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Abstract
Purpose To investigate the changes of color vision and cen-
tral visual field in a cohort of patients with Vogt–Koyanagi–
Harada (VKH) syndrome.
Methods Sixteen VKH patients (32 eyes) were enrolled in
this study. All the patients were treated with immunosup-
pressive agents. The best visual acuity, visual field testing
and color vision testing were available from the records in
all these patients at different time points, i.e. before treat-
ment and 1 month (±7 days), 3 months (±15 days), 6 months
(±20 days) and 12 months (±30 days) after treatment.
Results All patients showed active intraocular inflammation
at their first visit. A decreased visual acuity, abnormality of
color vision and abnormal visual field were observed at pre-
sentation. Visual acuity and color vision rapidly improved at 1
and 3 months and gradually improved thereafter. Visual field
defects significantly improved at 6 months and gradually
improved thereafter. However, visual field defects were still
observed in 27.5% of the tested patients following a 12-month
treatment. Color vision returned to the normal level only in
about one-third of these patients at this time point.
Conclusions Visual function was severely impaired in VKH
patients with active uveitis but rapidly improved following
immunosuppressive therapy. Visual fields are much more
severely affected by the disease than visual acuity and its
improvement lagged behind that of visual acuity and color
vision.
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Introduction
Vogt–Koyanagi–Harada (VKH) syndrome has generally
been considered as an autoimmune disease against melano-
cytes. It is characterized by choroiditis at the onset of
disease and a granulomatous uveitis at recurrence. A variety
of extraocular manifestations are associated with this syn-
drome [1–4]. It is more prevalent in certain pigmented races,
such as Asians and Native Americans [1–4]. Visual progno-
sis is generally favorable when prompt diagnosis was made
and appropriate immunosuppressive treatment was installed
[2, 5, 6].
The central visual acuity is considered to be an important
measurement of visual function and is an important indica-
tor of visual outcome in patients with VKH syndrome [2, 5].
However, in our clinical experience, some patients with
good or even normal central visual acuity still complain of
visual disturbances such as visual field defects or abnormal
color vision. In a recent study, we have revealed that certain
VKH patients with normal visual acuity have overt abnor-
malities when tested by multifocal electroretinography [7].
Therefore, visual acuity measurement alone is not a suffi-
cient parameter to accurately evaluate the retinal, especially
the macular function. Central visual field and color vision
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have been shown to be important parameters for visual
function [8]. In this study, we evaluated the alterations of
color vision and central visual field in patients with VKH
syndrome to better understand the effects of disease and
treatment on visual function.
Material and methods
This retrospective study included patients diagnosed as
VKH syndrome between January 1, 2006 and March 20,
2008. The diagnosis of VKH was based on detailed history
and clinical examinations described in an earlier study [5].
All patients included in this study met the revised criteria for
VKH syndrome by the International Nomenclature Com-
mittee [9]. A history or the presence of exudative retinal
detachment and pigmentary changes involving the macular
area was inquired or observed in all of the patients at first
visit or follow-up visit in our hospital. Hereditary color
vision defects were carefully inquired in each patient and
no color vision defects were reported by any of them.
Patients with conditions which might alter the color vision
and visual field values, such as a history of glaucoma,
presence of increased intraocular pressure, overt media
opacity, posterior synechiae, a history of previous ocular
surgery, or diabetes were excluded from the study.
The patients were followed up and examined using
Snellen charts at each visit following treatment. Visual field
testing and color vision testing were available from the
records in all these patients at different time points, i.e.
before treatment and 1 month (±7 days), 3 months
(±15 days), 6 months (±20 days) and 12 months (±30 days)
after treatment. These tests were performed in the routine
facilities of the institute and the technicians administering
the test were unaware of the diagnosis of the patients. A
thorough ophthalmological examination, including slit-lamp
biomicroscopy and ophthalmoscopy through a dilated pupil,
was performed in all patients. For the purpose of statistical
analysis, Snellen chart visual acuity was converted to the
logarithm of the minimal angle of resolution (log MAR)
value [10]. Visual fields were tested with the Humphrey
Field Analyzer Program 30–2 according to the Humphrey
perimetry manual. The efficiency of fixation of the subjects
was constantly monitored by an experienced perimetrist.
The mean deviation (MD, in decibels) and corresponding
P value of each field analysis was noted. The Farnsworth-
Munsell (FM) 100-hue test under standard illuminant C
conditions was performed to detect color vision defects [8].
For purpose of statistical analysis, normal visual acuity
was defined as best-corrected visual acuity (BCVA) with
equal to or better than 0.8 in this study. Visual fields with
false-positive responses of more than 15%, false-negative
responses, or a rate of fixation loss of more than 20% were
not included in this analysis. In this study, we used MD
and P value to evaluate the visual field abnormality. MD
value reflected the extensive damage of the retina. The
more severe the retina damage was, the lower value of
MD. Each P value corresponds to a MD value. The P value
indicates the probability of that MD being found in the
normal population. Color vision scores were determined
using the FM 100 testing which was performed in a
dark room with test materials viewed under standard
illuminant conditions. Subjects used near vision correc-
tion, if needed, and were given 2 min to complete each
of the four test boxes. The approximate distance from
the subjects’ eyes to the test materials was 30 to 50 cm.
Total error score was calculated according to the man-
ufacturer’s recommendations, and the square root of the
total error score was used in analyses. A high value
reflects a defect of color vision. For normal color vision
values, we chose data from a population of healthy
Chinese individuals previously reported by Huang and
associates [11] who also measured the color vision with
the FM 100 test.
The study followed the tenets of the World Medical Asso-
ciation Declaration of Helsinki. Informed consent was
obtained from all patients prior to these aforementioned
examinations and treatment with immunosuppressive agents.
The data were collected from the patients and were sub-
sequently entered into a computer-based data bank. Statisti-
cal analysis was performed using SAS for windows XP. The
ANOVAwas used to test the significance of the mean values
before treatment and the values at 1, 3, 6 and 12 months
after treatment. A P value less than or equal to 0.05 was
considered statistically significant.
Results
This retrospective study included 32 eyes of 16 patients.
There were nine males and seven females in the study
patients. The mean age was 33.2±9.6 years, ranged from
21 to 50 years old. All the patients with VKH syndrome had
an active intraocular inflammation at their first visit and
were treated with corticosteroids in combination with other
immunosuppressive agents such as cyclosporine or chlor-
ambucil. The ocular findings included diffuse choroiditis,
exudative retinal detachment, optic disk edema or overt
granulomatous anterior uveitis in association with ‘sun-set
glow’ fundus and nummular chorioretinal depigmented
scars.
The BCVA ranged from 20/250 to 20/25 (median
BCVA020/71) on Snellen charts, and the mean logMAR
value was 0.72 (SD00.42) before treatment. One month
after treatment, the BCVA ranged from 20/200 to 20/16
(median BCVA020/33), and the mean logMAR value was
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0.38 (SD00.26), significantly lower than that before treat-
ment (P00.026). Three months after treatment, the BCVA
ranged from 20/80 to 20/15 (median BCVA020/28), and the
mean logMAR value was 0.18 (SD00.10; P00.012). The
BCVA continued to improve at 6 months (median BCVA0
20/24, mean logMAR00.12±0.06, P<0.001) and 12 months
(median BCVA020/21, mean logMAR00.08±0.07, P<0.001;
Fig. 1). At the final follow-up, 81.3% of the eyes had a BCVA
of ≥20/25 and only 6.3% of the eyes had a BCVA below 20/40.
FM 100-hue testing showed that the mean total error score
(TES) in these patients was 365 (SD0135) before treatment.
One month after treatment, the mean TES decreased to 178
(SD091), showing a significant improvement (P00.029).
The mean TES was further improved at 3 months (124±56,
P<0.001), 6 months (78±46, P<0.001) and 12 months (52±
36, P<0.001; Fig. 2). However, the mean TES was still abnor-
mal in 65.6% of the tested patients at 12 months following
treatment.
The MD measured with the Humphrey Field Analyzer
ranged from 6.82 to 26.02 db, with a mean value of 15.62 db
(SD06.98) in the VKH patients before treatment. One month
after treatment, the MD value ranged from 6.20 to 17.59 db,
with a mean value of 13.64 (SD05.38; P00.102). Three
months later, the mean MD value was 8.20 db (SD02.80;
P00.087).The mean MD value was significantly improved at
6 months (4.34±1.58, P00.026) and 12 months (3.37±1.21,
P00.013; Fig 3). At 12 months following treatment, the MD
value returned to normal levels in 72.5% of these patients. The
mean P value was lower than 1.52% in the VKH patients
before treatment. One and 3 months after treatment, the
mean P value was lower than 0.72% (P00.448) and 0.76%
(P00.426), respectively. At 6 months after treatment, the
mean P value was lower than 2.32%, which was slightly
higher than that before treatment although there was no sta-
tistical difference (P00.325). After 12-month treatment, the
mean P value was lower than 3.86%, which was significantly
higher than that before treatment (P00.032).
Discussion
In this study, we evaluated the visual function of VKH patients
with active uveitis before and after treatment with immuno-
suppressive agents using visual acuity, color vision and visual
field. Our results showed that the patients displayed striking
abnormalities in these three parameters before treatment,
reflecting a severely impaired visual function in active VKH
syndrome. An improvement of visual acuity and color vision
was rapidly achieved at 1 and 3 months, followed by a gradual
recovery at 6 and 12 months after treatment. For the visual
field results, a marked amelioration was observed at 6 months
and thereafter following treatment. These results show that
there is a substantial recovery of visual function in VKH
patients following appropriate immunosuppressive treatment.
Among the three tested parameters, recovery of visual acuity
and color vision preceded an improvement of visual field.
Various studies have shown that visual acuity at presen-
tation is an important prognostic indicator of final visual
acuity in patients with VKH syndrome [2, 5]. Approximate-
ly 60–80% of patients could achieve a visual acuity of 20/40
or better [2, 5, 6]. In our patients, we found that more than
90% had a visual acuity of 20/40 or better at the final
Fig. 1 Time course of best-corrected visual acuity (in terms of Log-
MAR) following immunotherapy in VKH eyes, the plots mean the
average of the test, the error bars mean standard deviation: SD
Fig. 2 Time course of color vision changes (in terms of total error
score, TES) following immunotherapy in VKH eyes, the plots mean
the average of the test, the error bars mean standard deviation: SD
Fig. 3 Time course of visual field changes (in terms of mean devia-
tion, MD) following immunotherapy in VKH eyes, the plots mean the
average of the test, the error bars mean standard deviation: SD
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follow-up. Furthermore, a rapid decrease of the logMAR
value was observed at 1 and 3 months following treatment,
indicating a prompt recovery of visual acuity in VKH
patients following appropriate treatment. This result is gen-
erally consistent with that reported by Rubsamen et al. [12].
A number of tests have been designed for color vision
screening and grading. The Farnsworth–Munsell 100-hue
test is designed to measure hue discrimination ability at a
constant value and chroma and is considered an excellent
choice in evaluating color vision defects [13].To rule out
other causes of color vision defects, we excluded patients
with conditions which could influence the color vision.
Interestingly, we found that abnormal color vision was pres-
ent in all the examined VKH patients with active uveitis. As
color vision generally reflects the function of retinal cone
cells [14], it is reasonable to presume that these cells were
severely involved during VKH syndrome. Our results are in
agreement with previous reports in which abnormal color
vision is common in retinochoroidal or optic nerve disor-
ders, such as diabetic retinopathy, tilted disc syndrome,
optic neuritis and primary open angle glaucoma [15–18].
Abnormal color vision has also been reported in birdshot
choroiretinopathy [19]. It is unknown whether abnormal
color vision is a universal finding of uveitis involving the
choroid and retina. Further study is required to clarify this
issue. Similar to visual acuity, color vision rapidly improved
after immunosuppressive treatment.
Visual field is another important parameter to evaluate
visual function. Our study showed severe visual field abnor-
malities in VKH patients before treatment as evidenced by
severely decreased MD value and P value. Visual field has
been shown to reflect the function of the retina, choroid and
optic nerve [20]. There are numerous field abnormalities
observed in ocular fundus diseases. The impaired visual field
is generally in accordance with the inflammatory damage to
the choroid and its adjacent tissues observed in this syndrome.
Clinically, this disease is characterized by choroiditis, chorior-
etinitis and neuroretinitis at its first attack [2, 5]. Pathological-
ly, marked losses of melanocytes and infiltration of
lymphocytes in the choroid, and destruction or hyperplasia
of retinal pigment epithelium (RPE) have been described in
VKH syndrome [21]. In addition, fundus fluorescein angiog-
raphy [22], indocyanine green angiography [23] and optical
coherence tomography [24] also showed a variety of changes
in the choroid, retina and RPE. Similar to visual acuity and
color vision, central visual field also significantly improved
following appropriate treatment. However, it is unexpected
that the recovery of both the MD value and P value lagged
behind that of visual acuity. The visual field results are in
general accordance with those presented by Gordon et al. [20]
in birdshot choroiretinopathy. They also found that the visual
field test is independent of other measures of visual dysfunc-
tion and that visual field recovery lagged behind that of visual
acuity. These observations may suggest important features
concerning the pathology of both diseases. More studies are
needed to clarify this issue. An unsynchronized recovery of
visual acuity, central visual field and color vision in patients
with VKH syndrome suggests that sub-clinical abnormal
macular function is still present in certain patients although
the intraocular inflammation is completely controlled.
In summary, our studies showed that a severely decreased
visual acuity was associated with abnormal color vision and
visual field defects in patients with active VKH syndrome.
Following appropriate immunosuppressive treatment, improve-
ment of visual acuity and color vision was faster than
that of the visual field. Both color vision and visual field
parameters may provide additional quantifiable measurements
of visual dysfunction in patients with VKH syndrome. How-
ever, it is not yet known whether visual field or color vision at
baseline is a better predictor of final visual acuity. Further
studies are needed to clarify this issue.
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